Lower-dose intradermal treatment has been better tolerated and associated with improvement in airway hyper-responsiveness, late-phase skin test

response to whole allergen, reduction in selleck chemicals nasal symptoms together with up-regulation of CD4+ T cells producing IFN-γ cells but not regulatory T cells following cat peptide immunotherapy [126–130]. It is also possible to induce in-vivo production of allergen by vaccinating with DNA encoding the allergen. While this often produces a Th1-biased response, it is highly dependent on the DNA construct and mode of delivery. Clinical studies of these agents have not progressed [131]. Recombinant allergens offer the hope of better standardization, but their biological efficacy has been uncertain. Recombinant BetV1 protein has also been proven to be as effective as native BetV1 or conventional birch pollen extract in birch pollen SCIT [132,133], and in a recent clinical trial recombinant grass pollen vaccine has also been shown to be clinically safe and effective Selumetinib purchase [134]. Use of recombinant allergens may not only be safer, but may also allow patient-specific vaccines to be produced based on the individual’s

in vitro IgE reactivity pattern. While current native allergen vaccines modulate the patient’s existing allergen-specific IgE, they can also induce new sensitizations to other epitopes of the allergen, previously not present in the patient’s serum. The clinical consequences of this, if any, are not known, so any clinical advantage of vaccines based on component-resolved diagnostics remains to be demonstrated. Enhancement of the allergen with adjuvants itself is not new. Enzyme-potentiated immunotherapy represented an early attempt to increase the potency of the allergen selleck products by adding a β-glucuronidase, protamine sulphate and cyclohexanediol. It was not widely adopted, and was shown subsequently to be ineffective [135]. Another adjuvant, monophosphoryl lipid A (MPL) has been investigated

in allergy vaccines. MPL is a purified lipopolysaccharide extracted from the cell walls of Salmonella minnesota[136–138] and induces a Th1 response via Toll-like receptor-4. A large recent multi-centre study with pollen allergoids adsorbed on L-tyrosine formulated with MPL has shown good efficacy and tolerability. Other adjuvants that have been investigated for their strong Th1-evoking ability include immunostimulatory DNA sequences [139] (ISS) and heat-killed Mycobacterium vaccae[140]. The latter need further investigation in clinical trials. Many alternative modes of allergen delivery for specific immunotherapy (SIT) aim to induce a T cell response but avoid IgE-binding. Because allergen is presented to T cells in the context of MHC class II, steering allergen towards this pathway is an attractive possibility.